Neurol. praxi. 2012;13(4):216-218

Genetic testing in idiopathic epileptic syndromes and epileptic encephalopathies - part I

MUDr.Hana Krijtová, doc.MUDr.Petr Marusič, Ph.D.
Centrum pro epilepsie Motol, Neurologická klinika 2. LF UK a FN Motol, Praha

Molecular genetic diagnostic methods have recently very quickly advanced, their yield has simultaneously increased and the cost decreased.

Both physicians and common population have become more aware of possible genetic reasons for epilepsy and demands for

genetic testing of patients with epilepsy have increased too. But despite the progress in identification of genes contributing to different

epileptic syndromes the utility of genetic tests in clinical epileptology is often controversial. In genetic counselling physicians should be

familiar not only with the mode of inheritance of disorders, but must be also aware of frequent genetic and phenotype heterogenicity

and clinical utility of the tests. The overview of idiopathic epileptic syndromes and epileptic encephalopathies with identified genetic aetiology,

possibilities of genetic testing and current opinion on the clinical utility of genetic testing in specific syndromes is provided.

Keywords: idiopathic epileptic syndromes, epileptic encephalopathies, genetic testing

Published: July 31, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Krijtová H, Marusič P. Genetic testing in idiopathic epileptic syndromes and epileptic encephalopathies - part I. Neurol. praxi. 2012;13(4):216-218.
Download citation

References

  1. Cossette P, Liu L, Brisebois K, Dong H, Lortie A, Vanasse M, Saint-Hilaire JM, Carmant L, Verner A, Lu WY, Wang YT, Rouleau GA. Mutation of GABRA1 in an autosomal dominant form of juvenile myoclonic epilepsy. Nat Genet 2002; 31(2): 184-189. Go to original source... Go to PubMed...
  2. Dibbens LM, Feng HJ, Richards MC, Harkin LA, Hodgson BL, Scott D, Jenkins M, Petrou S, Sutherland GR, Scheffer IE, Berkovic SF, Macdonald RL, Mulley JC. GABRD encoding a protein for extra- or peri-synaptic GABAA receptors is a susceptibility locus for generalized epilepsies. Hum Mol Genet 2004; 13(13): 1315-1319. Go to original source... Go to PubMed...
  3. Escayg A, De Waard M, Lee DD, Bichet D, Wolf P, Mayer T, Johnston J, Baloh R, Sander T, Meisler MH. Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet 2000; 66(5): 1531-1539. Go to original source... Go to PubMed...
  4. Greenberg DA, Cayanis E, Strug L, Marathe S, Durner M, Pal DK, Alvin GB, Klotz I, Dicker E, Shinnar S, Bromfield EB, Resor S, Cohen J, Moshe SL, Harden C, Kang H. Malic enzyme 2 may underlie susceptibility to adolescent-onset idiopathic generalized epilepsy. Am J Hum Genet 2005; 76(1): 139-46. Go to original source... Go to PubMed...
  5. Haddow J, Palomaki G. ACCE: A model process for evaluating data on emerging genetic test.. In: M., K, J., L, W., B, editors. Human Genetic Epidemiology. New York: Oxford University Press; 2004. p. 217-233.
  6. Helbig I, Mefford HC, Sharp AJ, Guipponi M, Fichera M, Franke A, Muhle H, de Kovel C, Baker C, von Spiczak S, Kron KL, Steinich I, Kleefuss-Lie AA, Leu C, Gaus V, Schmitz B, Klein KM, Reif PS, Rosenow F, Weber Y, Lerche H, Zimprich F, Urak L, Fuchs K, Feucht M, Genton P, Thomas P, Visscher F, de Haan GJ, Moller RS, Hjalgrim H, Luciano D, Wittig M, Nothnagel M, Elger CE, Nurnberg P, Romano C, Malafosse A, Koeleman BP, Lindhout D, Stephani U, Schreiber S, Eichler EE, Sander, T. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet 2009; 41(2): 160-162. Go to original source... Go to PubMed...
  7. Chen Y, Lu J, Pan H, Zhang Y, Wu H, Xu K, Liu X, Jiang Y, Bao X, Yao Z, Ding K, Lo WH, Qiang B, Chan P, Shen Y, Wu X. Association between genetic variation of CACNA1H and childhood absence epilepsy. Ann Neurol 2003; 54(2): 239-243. Go to original source... Go to PubMed...
  8. Nakayama J, Fu YH, Clark AM, Nakahara S, Hamano K, Iwasaki N, Matsui A, Arinami T, Ptacek LJ. A nonsense mutation of the MASS1 gene in a family with febrile and afebrile seizures. Ann Neurol 2002; 52(5): 654-657. Go to original source... Go to PubMed...
  9. Niemeyer M, Cid L, Sepúlveda F, Blanz J, Auberson M, Jentsch T. No evidence for a role of CLCN2 variants in idiopathic generalized epilepsy. Nat Genet. 2010; 42(1): 3. Go to original source... Go to PubMed...
  10. Ottman R, Hirose S, Jain S, Lerche H, Lopes-Cendes I, Noebels JL, Serratosa J, Zara F, Scheffer IE. Genetic testing in the epilepsies-report of the ILAE Genetics Commission. Epilepsia 2010; 51(4): 655-670. Go to original source... Go to PubMed...
  11. Pal DK, Evgrafov OV, Tabares P, Zhang F, Durner M, Greenberg DA. BRD2 (RING3) is a probable major susceptibility gene for common juvenile myoclonic epilepsy. Am J Hum Genet 2003; 73(2): 261-270. Go to original source... Go to PubMed...
  12. Suzuki T, Delgado-Escueta AV, Aguan K, Alonso ME, Shi J, Hara Y, Nishida M, Numata T, Medina MT, Takeuchi T, Morita R, Bai D, Ganesh S, Sugimoto Y, Inazawa J, Bailey JN, Ochoa A, Jara-Prado A, Rasmussen A, Ramos-Peek J, Cordova S, RubioDonnadieu F, Inoue Y, Osawa M, Kaneko S, Oguni H, Mori Y, Yamakawa K. Mutations in EFHC1 cause juvenile myoclonic epilepsy. Nat Genet 2004; 36(8): 842-849. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.